Agreements reached under this partnership
Capital and Business Alliance- 1
By combining the GA measurement technology being developed by PROVIGATE with our digital immunoassay technology, or D-IA, we aim to provide at-home blood glucose monitoring POCT services to the vast diabetes and prediabetes market in Japan and overseas.
- 2
Over the medium to long term, the companies aim to establish this service as a new standard model for at-home blood glucose monitoring, primarily for people with type 2 diabetes, and to obtain reimbursement coverage and expand adoption in Japan and overseas.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
At this time, we expect this basic agreement to have a limited impact on the company's near-term results. If it becomes clear that the agreement will have a material impact, we will disclose the information promptly.
| Item | Details |
|---|---|
| Name of alliance partner | PROVIGATE Co., Ltd. |
| Alliance partner's business activities | Development of at-home blood glucose monitoring devices and applications |
| Alliance partner's location | Bunkyo-ku, Tokyo |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | By combining the GA measurement technology being developed by PROVIGATE with our digital immunoassay technology, or D-IA, we aim to provide at-home blood glucose monitoring POCT services to the vast diabetes and prediabetes market in Japan and overseas., Over the medium to long term, the companies aim to establish this service as a new standard model for at-home blood glucose monitoring, primarily for people with type 2 diabetes, and to obtain reimbursement coverage and expand adoption in Japan and overseas. |
| Acquisition price | Not disclosed |
| Impact on Business Performance | At this time, we expect this basic agreement to have a limited impact on the company's near-term results. If it becomes clear that the agreement will have a material impact, we will disclose the information promptly. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide an at-home blood glucose monitoring POCT service by combining PROVIGATE's GA measurement technology with タウンズ' digital immunoassay technology. In addition, the companies aim to establish diabetes as a priority area in their growth strategy and to obtain reimbursement coverage and expand adoption in Japan and overseas.